ASE-C-POP Framework Chart: Medication Issues Guide

Read the constraint before the content, because this brief penalises format failures more harshly than most and says so in capitals: failure to comply with any of the guidelines will result in zero marks. The whole chart, every section of it, must fit inside two A4 pages at Times New Roman no smaller than 11 point with the template's margins untouched. References sit outside that limit, which is the one piece of headroom you are given. You may resize the individual cells — a larger therapeutic plan box at the expense of a smaller background box is explicitly allowed — but you may not resize the page. That single rule should shape how you write every entry, because a chart is not a place for paragraphs and the two-page ceiling is what forces the concision the assessment is really testing.

The task itself is a medication review, not an essay about one. You are asked to *identify any actual or potential medication issues* and then *create a plan to solve these issues*, and both halves have to appear. An actual issue is one the patient has now: a drug interaction in the current regimen, a dose outside the recommended range for their renal function, a duplicate therapy, an untreated indication. A potential issue is one the regimen creates risk of: cumulative anticholinergic burden, a fall risk that has not yet produced a fall, monitoring that is due and not scheduled. Separating the two explicitly is the easiest way to demonstrate you understood the instruction, and it also stops the chart becoming a list of everything slightly imperfect about the prescription. Say which category each finding belongs to in the cell itself, because a marker reading a dense chart should not have to infer whether you thought a problem was already happening or merely likely to.

ASE-C-POP is a structured framework, so use its structure rather than writing around it. Each element exists to make you state something you would otherwise leave implicit — the assessment of the problem, the supporting evidence, the plan and its outcome measures. The commonest failure is filling the assessment cells thoroughly and then treating the plan cells as a formality. The plan is where the marks concentrate, because anyone can notice that a patient is on two drugs from the same class; the skill is saying which one goes, at what rate, what replaces it, who does it, and what you will measure to know whether it worked. Read the framework article the brief links before you start, since a chart filled in without understanding the framework reads exactly like one. The outcome element is also what makes the plan auditable, since a recommendation nobody can check later is indistinguishable from a suggestion, and this framework exists precisely to close that gap.

Every claim in the chart needs a reference, and the brief specifies QUT numbered referencing with a link to the library instructions. This is not a stylistic preference you can substitute for APA out of habit — it is one of the guidelines whose breach the brief says costs everything. Numbered referencing also changes how you write: sources are cited by number in the order they first appear, which suits a chart well because a superscript number costs almost no space inside a cramped cell. Build the reference list as you go rather than at the end, because renumbering a chart after the fact is where errors get introduced, and confirm the reference list sits outside the two-page count so you are not sacrificing clinical content to accommodate it. Check the library instructions rather than reproducing a numbered style from memory, because the punctuation and ordering conventions differ between numbered systems and the brief points you at one specific set.

Your evidence should be specific to this patient rather than general to the drug. A guideline statement that a medicine requires renal dose adjustment is background; the finding that *this* patient's estimated clearance places them below the threshold is the assessment. Prioritise the issues too, because two pages will not hold everything and an unprioritised chart implies you could not tell which problem mattered. Lead with what could cause harm soonest, then what is ineffective, then what is merely suboptimal. If a genuine issue will not fit, it is better to state it briefly with a plan than to develop a minor one fully — the marker is assessing clinical judgement, and judgement is visible in what you chose to leave out as much as in what you included. Say why you deprioritised something if space forced the decision, since one line acknowledging a lesser issue shows the marker you saw it and chose, rather than leaving them to assume you missed it.

Since the patient case study is supplied separately in the assignment folder, check that you are working from the current version before you write anything, and read it for what it does not say as well as what it does. Missing information is itself a finding in a medication review: an unrecorded allergy status, no recent bloods, an unclear indication for a long-term prescription. Note those as issues with a plan to resolve them rather than assuming values that suit your argument. If this is a group submission, agree the prioritisation and the two-page layout before anyone drafts, because merging four independently written sections into a fixed page limit is the version of this assignment that runs out of space the night before it is due. Version control matters here too, because a two-page chart assembled from several contributors is easy to overrun silently when one person's edit pushes a table row onto a third page nobody rechecked.